Treatment of mgmt deficient cancer with 2-fluoroethyl-substituted nitrosoureas and other compounds
AssigneeYale University
InventorsSeth Herzon, Ranjit Bindra, Kingson Lin
Life of this patent
Estimating the term…
Abstract
Disclosed are nitrosourea and other compounds, pharmaceutical composition, and methods of treating cancers that are MGMT deficient regardless of their MMR status and particularly compounds, pharmaceutical compositions, and methods of treating cancers that are both MGMT and MMR deficient.
Claims12
A method for treating, ameliorating, or preventing an MGMT deficient cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically-effective amount of a compound of formula (I), or a pharmaceutically-acceptable salt thereof:
- wherein:
- R′ is selected from the group consisting of O and NH;
- and
- R is selected from the group consisting of H, NO2, CH2CH2Cl, CH2CH2F, cyclohexyl,
- 4-methylcyclohexyl, —C(H)(CH3)—P(═O)(OCH2CH3)2,
- .
A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically-acceptable salt thereof, and at least one pharmaceutically-acceptable carrier or excipient:
- wherein:
- R′ is selected from the group consisting of O and NH;
- and
- R is selected from the group consisting of H, NO2, C2H4Cl, C2H4F, cyclohexyl, 4-
- methylcyclohexyl, —C(H)(CH3)—P(═O)(OCH2CH3)2,
- .
A compound of formula (I), or a pharmaceutically-acceptable salt thereof:
- wherein:
- R′ is selected from the group consisting of O and NH;
- and
- R is selected from the group consisting of NO2, —C(H)(CH3)—P(═O)(OCH2CH3)2,
- .
Dependencies are inferred from the claim text.